|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS11449 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-TEC/Tec protein tyrosine kinase |
| 克隆性 | |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human TEC/Tec protein tyrosine kinase |
產(chǎn)品訂購信息：
英文名稱 Anti-TEC/Tec protein tyrosine kinase
中文名稱 TEC酪氨酸激酶蛋白抗體費(fèi)用
別 名 MGC126760; MGC126762; PSCTK4; Tec; Tec protein tyrosine kinase; TEC_HUMAN; Tyrosine protein kinase; Tyrosine-protein kinase Tec.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 免疫學(xué) 信號轉(zhuǎn)導(dǎo) 激酶和磷酸酶
蛋白分子量 predicted molecular weight: 74kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human TEC/Tec protein tyrosine kinase
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
TEC酪氨酸激酶蛋白抗體費(fèi)用 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 TEC is a belongs to the Tec family of non-receptor protein-tyrosine kinases containing a pleckstrin homology domain. Tec family kinases are involved in the intracellular signaling mechanisms of cytokine receptors, lymphocyte surface antigens, heterotrimeric G-protein coupled receptors, and integrin molecules. They are also key players in the regulation of the immune functions. Tec kinase is an integral component of T cell signaling and has a distinct role in T cell activation. This gene may be associated with myelodysplastic syndrome.
Function : Non-receptor tyrosine kinase that contributes to signaling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. Plays a redundant role to ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. Required for TCR-dependent IL2 gene induction. Phosphorylates DOK1, one CD28-specific substrate, and contributes to CD28-signaling. Mediates signals that negatively regulate IL2RA expression induced by TCR cross-linking. Plays a redundant role to BTK in BCR-signaling for B-cell development and activation, especially by phosphorylating STAP1, a BCR-signaling protein. Required in mast cells for efficient cytokine production. Involved in both growth and differentiation mechanisms of myeloid cells through activation by the granulocyte colony-stimulating factor CSF3, a critical cytokine to promoting the growth, differentiation, and functional activation of myeloid cells. Participates in platelet signaling downstream of integrin activation. Cooperates with JAK2 through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. GRB10, a negative modifier of the FOS activation pathway, is another substrate of TEC. TEC is involved in G protein-coupled receptor- and integrin-mediated signalings in blood platelets. Plays a role in hepatocyte proliferation and liver regeneration and is involved in HGF-induced ERK signaling pathway. TEC regulates also FGF2 unconventional secretion (endoplasmic reticulum (ER)/Golgi-independent mechanism) under various physiological conditions through phosphorylation of FGF2 'Tyr-215'. May also be involved in the regulation of osteoclast differentiation.
Subunit : Interacts with INPP5D/SHIP1 and INPPL1/SHIP2. Interacts with CD28, FASLG, FGF2, GRB10, LYN and KIT. Interacts with VAV1 and JAK2 (By similarity).
Subcellular Location : Cytoplasm. Cell membrane; Peripheral membrane protein. Cytoplasm, cytoskeleton. Note=Following B-cell or T-cell receptors activation by antigen, translocates to the plasma membrane through its PH domain. Thrombin and integrin engagement induces translocation of TEC to the cytoskeleton during platelet activation. In cardiac myocytes, assumes a diffuse intracellular localization under basal conditions but is recruited to striated structures upon various stimuli, including ATP (By similarity).
Tissue Specificity : Expressed in a wide range of cells, including hematopoietic cell lines like myeloid, B-, and T-cell lineages.
Post-translational modifications : Following B-cell or T-cell receptors engagement, translocates to the plasma membrane where it gets phosphorylated at Tyr-519. Undergoes also tyrosine phosphorylation during platelet activation.
Similarity : Belongs to the protein kinase superfamily. Tyr protein kinase family. TEC subfamily.
Contains 1 Btk-type zinc finger.
Contains 1 PH domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
Contains 1 SH3 domain.
Database links : UniProtKB/Swiss-Prot: P42680.2
Anti-Phospho-TAK1 (Ser412)/FITC 熒光素標(biāo)記磷酸化轉(zhuǎn)化生長因子β活化激酶1抗體IgGMulti-class antibodies規(guī)格： 0.2ml
APG4B/AUTL1 APG4B細(xì)胞自噬相關(guān)抗原Multi-class antibodies規(guī)格： 0.5mg
Rho相關(guān)蛋白激酶2抗體 Anti-ROCK2 0.1ml
SCYLV 英文名稱： 甘蔗SCYLV抗體 0.2ml
EML4 英文名稱： 限制過度增殖相關(guān)蛋白EML4抗體 0.2ml
Rhesus antibody Rh phospho-MK1+MK2(Ser222/Ser226) 磷酸化原活化蛋白激酶1抗體 規(guī)格 0.1ml
APG4B/AUTL1 APG4B細(xì)胞自噬相關(guān)抗原Multi-class antibodies規(guī)格： 0.5mg
Anti-TLK1/FITC 熒光素標(biāo)記調(diào)節(jié)染色體組裝激酶1抗體IgGMulti-class antibodies規(guī)格： 0.2ml
NR2B (Glutamate receptor) 谷氨酸受體(抗原)Multi-class antibodies規(guī)格： 0.5mg
新型基因抗體 Anti-TBX2 0.1ml
phospho-SYN1(Ser603) 英文名稱： 磷酸化神經(jīng)突觸素1抗體 0.1ml
phospho-Ephrin B (Ty*9) 英文名稱： 磷酸化Ephrin B抗體 0.1ml
Rhesus antibody Rh phospho-LKB1(Ser428) 磷酸化絲氨酸/蘇氨酸蛋白激酶抗體 規(guī)格 0.1ml
NR2B (Glutamate receptor) 谷氨酸受體(抗原)Multi-class antibodies規(guī)格： 0.5mg
P53(wt-p53) 抑制基因抗原(野生型P53)Multi-class antibodies規(guī)格： 0.5mg
Anti-ASPP1 p53凋亡刺激蛋白1抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh phospho-AQP2(Ser264) 磷酸化水通道蛋白2抗體 規(guī)格 0.1ml
TdT 末端脫氧核苷酸轉(zhuǎn)移酶 濃縮液 0.1ml 進(jìn)口分裝
Ube2N 英文名稱： 泛素蛋白連接酶2N抗體 0.2ml
DHRSX 英文名稱： 短鏈脫氫酶/還原酶家族X抗體 0.2ml
Anti-ASPP1 p53凋亡刺激蛋白1抗體Multi-class antibodies規(guī)格： 0.2ml
IL15 Protein Human 重組人 IL-15 / IL15 / Ierleukin 15 蛋白 (His 標(biāo)簽)
小鼠牙細(xì)胞完全培養(yǎng)基 100mL
HA Others H1N1 甲型 H1N1 (A/Beijing/22808/2009) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽性對照)
NCI-H929-CMV-EGFP(穩(wěn)定株)人細(xì)胞 NCI-H929-CMV-EGFP (stable sain) human myeloma cell 1640+20% FBS(熱滅活)
CM-H044人肝動脈內(nèi)皮細(xì)胞完全培養(yǎng)基100mL
人小神經(jīng)膠質(zhì)細(xì)胞(HM) ( 5×105 ) 人海馬神經(jīng)元 Human
CM-H097人椎間盤髓核細(xì)胞完全培養(yǎng)基100mL
IL10RA Others Cynomolgus 食蟹猴 IL10RA 人細(xì)胞裂解液 (陽性對照)
人肺動脈平滑肌細(xì)胞HPASMC
RWPE2細(xì)胞，人上皮細(xì)胞 兔晶體上皮細(xì)胞永生系,N/N1003A(RLE)細(xì)胞 小鼠心肌細(xì)胞MCM
LLC-WRC 256(大鼠腹水癌細(xì)胞) 5×106cells/瓶×2
ACHN(人細(xì)胞) 5×106cells/瓶×2 CM-R043大鼠小腸平滑肌細(xì)胞完全培養(yǎng)基100mL 人胚肺二倍體細(xì)胞;HEL-1
TEC酪氨酸激酶蛋白抗體費(fèi)用 IL15 Protein Human 重組人 IL-15 / IL15 / Ierleukin 15 蛋白 (His 標(biāo)簽)
小鼠牙細(xì)胞完全培養(yǎng)基 100mL
HA Others H1N1 甲型 H1N1 (A/Beijing/22808/2009) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽性對照)
NCI-H929-CMV-EGFP(穩(wěn)定株)人細(xì)胞 NCI-H929-CMV-EGFP (stable sain) human myeloma cell 1640+20% FBS(熱滅活)
CM-H044人肝動脈內(nèi)皮細(xì)胞完全培養(yǎng)基100mL
人小神經(jīng)膠質(zhì)細(xì)胞(HM) ( 5×105 ) 人海馬神經(jīng)元 Human
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. TEC酪氨酸激酶蛋白抗體費(fèi)用 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時,或位于酶的催化位點(diǎn)時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）TEC酪氨酸激酶蛋白抗體費(fèi)用 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力。抗體的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
